2023
Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET
Authors:
Therriault, J.**, Lussier, F. Z., Tissot, C.**, Chamoun, M., Stevenson, J., Rahmouni, N.**, Pallen, V., Bezgin, G., Servaes, S., Kunach, P.**, Wang, Y. T.**, Fernandez-Arias, J.**, Vermeiren, M., Pascoal, T. A., Massarweh, G., Vitali, P., Soucy, J. P., Saha-Chaudhuri, P., Gauthier, S.*, & Rosa-Neto, P.*
Journal:
Alzheimer's & dementia
Abstract
Introduction: [18F]AZD4694 is an amyloid beta (Aβ) imaging agent used in several observational studies and clinical trials. However, no studies have yet published data on longitudinal Aβ accumulation measured with [18F]AZD4694.
Methods: We assessed 146 individuals who were evaluated with [18F]AZD4694 at baseline and 2-year follow-up. We calculated annual rates of [18F]AZD4694 change for clinically defined and biomarker-defined groups.
Results: Cognitively unimpaired (CU) older adults displayed subtle [18F]AZD4694 standardized uptake value ratio (SUVR) accumulation over the follow-up period. In contrast, Aβ positive CU older adults displayed higher annual [18F]AZD4694 SUVR increases. [18F]AZD4694 SUVR accumulation in Aβ positive mild cognitive impairment (MCI) and dementia was modest across the neocortex.
Discussion: Larger increases in [18F]AZD4694 SUVR were observed in CU individuals who had abnormal amyloid positron emission tomography levels at baseline. [18F]AZD4694 can be used to monitor Aβ levels in therapeutic trials as well as clinical settings, particularly prior to initiating anti-amyloid therapies.
Keywords: Alzheimer’s disease; amyloid beta; positron emission tomography.
Share
Receive the
latest news
Stay updated with the latest research developments from CCNA-CCNV. Our news section provides insights into cutting-edge studies, advancements in dementia care, and key findings in brain health research.
